Comorbidities in Type 2 Diabetes Mellitus

New Valley University

Status: Enrolling

Conditions: Type 2 Diabetes

Treatments: Procedure: Electrocardiography (ECG); Procedure: Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound; Diagnostic Test: Complete blood count; Diagnostic Test: Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides; Diagnostic Test: AST, ALT, albumin; Diagnostic Test: Serum creatinine and estimated glomerular filtration rate; Diagnostic Test: Thyroid-stimulating hormone; Diagnostic Test: Serum iron, TIBC, Transferrin saturation and serum ferritin if needed; Diagnostic Test: Urine analysis and urinary albumin-to-creatinine ratio; Procedure: Arterial duplex ultrasound of both lower limbs; Diagnostic Test: Random blood glucose; Diagnostic Test: HBA1C

Study type: Interventional

Funder types: Other

Identifiers

NCT05874141

CODM2KNV

Details and patient eligibility

About

Type 2 diabetes mellitus (DM) has adopted a top priority as it is a disease with an increasing prevalence. The number of people living with DM has increased more than fourfold over the past 40 years to more than 460 million people today

Full description

All-cause mortality rates have declined substantially in several high-income countries, including England.

A diversification in non-fatal conditions in people with DM has also been reported. This is attributable to broader, non-vascular conditions. Due to increasing longevity among people with type 2 DM with increasing and diversifying multimorbidity in them, the health needs of people with Type 2 DM are therefore likely to be broad, and complex.

Finding multimorbidity (two or more chronic conditions) is common in people with Type 2 DM and increasing, but the comorbidity profiles of people with T2DM vary substantially.

Many studies have primarily focused on identifying multimorbidity patterns in the general population.

The understanding of multimorbidity patterns and composition of specific comorbidities in people with DM, and how this varies across patient groups and during the course of the disease, is limited. Further knowledge of this could provide insight into providing more holistic and more personal approaches to clinical guideline development, care pathways, and secondary prevention.

Enrollment: 288 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with type 2 diabetes.

Exclusion criteria

1. Patients with type 1 diabetes.
2. Patients with secondary diabetes.

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

288 participants in 1 patient group

type 2 DM

Other group

Treatment:

Diagnostic Test: HBA1C

Diagnostic Test: Random blood glucose

Diagnostic Test: AST, ALT, albumin

Diagnostic Test: Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides

Procedure: Arterial duplex ultrasound of both lower limbs

Diagnostic Test: Complete blood count

Diagnostic Test: Urine analysis and urinary albumin-to-creatinine ratio

Diagnostic Test: Serum iron, TIBC, Transferrin saturation and serum ferritin if needed

Diagnostic Test: Thyroid-stimulating hormone

Diagnostic Test: Serum creatinine and estimated glomerular filtration rate

Procedure: Transthoracic echocardiography, Neck ultrasonography if needed and abdominopelvic ultrasound

Procedure: Electrocardiography (ECG)